{"podcast":{"title":"Ion Genomics Podcast","slug":"ion-genomics-podcast-7831901","podcast_index_feed_id":7831901,"rss_url":"https://api.riverside.com/hosting/bjJ8IM8g.rss","website_url":"www.iongenomics.bio","image_url":"https://hosting-media.riverside.com/media/podcasts/33a5b670-e982-44e8-9d9e-9861ff1bad6b/logos/36dbc099-5e7f-409e-9b79-08546d4716e4.png","author":"Andrew P. Han","episode_count":7,"summary":"Ion Genomics brings you in-depth but also wide-ranging conversations with leading figures in genomic science and technology. Hosted by veteran science journalist Andrew P. Han, the Ion Genomics Podcast is a weekly window into the latest advances driving exploration of human biology. For more science and business news, check out www.iongenomics.bio and subscribe to the newsletter.","last_synced_at":"2026-06-26T18:20:24.653237+00:00","page_url":"https://stenobird.com/podcast/ion-genomics-podcast-7831901"},"episode":{"title":"Q1 Company News Roundup with Wall Street Analyst Kyle Mikson","slug":"q1-company-news-roundup-with-wall-street-analyst-kyle-mikson","published_at":"2026-06-12T15:24:47+00:00","page_url":"https://stenobird.com/podcast/ion-genomics-podcast-7831901/q1-company-news-roundup-with-wall-street-analyst-kyle-mikson","show_page_url":"https://stenobird.com/podcast/ion-genomics-podcast-7831901","url":"https://api.riverside.com/hosting-analytics/media/65c672cc22b541b912889eb78e3429b4c9418b4b6829097b00761cae43934eba/eyJlcGlzb2RlSWQiOiJlNGJkNWI3ZC04ZTY3LTRlODYtYmY4NC02ZTM4OWMzMWU3NWUiLCJwb2RjYXN0SWQiOiIzM2E1YjY3MC1lOTgyLTQ0ZTgtOWQ5ZS05ODYxZmYxYmFkNmIiLCJhY2NvdW50SWQiOiI2OWIzMTk0ZDExZTc3MTlhNjFmZmRmNTYiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyYzIzZWQ1NzhlOWEzODIzNTk2N2ZlL2FuZHJldy1oYW5zLXN0dWRpby1HZ25NUy1jb21wb3Nlci0yMDI2LTYtMTJfXzE3LTIxLTE3Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/65c672cc22b541b912889eb78e3429b4c9418b4b6829097b00761cae43934eba/eyJlcGlzb2RlSWQiOiJlNGJkNWI3ZC04ZTY3LTRlODYtYmY4NC02ZTM4OWMzMWU3NWUiLCJwb2RjYXN0SWQiOiIzM2E1YjY3MC1lOTgyLTQ0ZTgtOWQ5ZS05ODYxZmYxYmFkNmIiLCJhY2NvdW50SWQiOiI2OWIzMTk0ZDExZTc3MTlhNjFmZmRmNTYiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyYzIzZWQ1NzhlOWEzODIzNTk2N2ZlL2FuZHJldy1oYW5zLXN0dWRpby1HZ25NUy1jb21wb3Nlci0yMDI2LTYtMTJfXzE3LTIxLTE3Lm1wMyJ9.mp3","summary":"What kind of market share can Illumina expect when it launches its own MRD kits and is it worth the risk of annoying customers that also offer those tests? Why did liquid biopsy company stocks do so well in May? What were his headline takeaways from the recent American Society of Clinical Oncology annual meeting? Where is he going on summer vacation after a hectic several months? Tune in to hear the answers to these questions, and more. If you’re interested in learning more about Kyle’s takes on the life science tools and diagnostics industries, you can reach out to him on LinkedIn to start a conversation. https://www.linkedin.com/in/kylemiksoncfa/ For full disclosure, he asked me to note that Seer is an investment banking client of Canaccord Genuity.","meta_description":"What kind of market share can Illumina expect when it launches its own MRD kits and is it worth the risk of annoying customers that also offer those tests…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2679,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/ion-genomics-podcast-7831901/episodes/q1-company-news-roundup-with-wall-street-analyst-kyle-mikson/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/ion-genomics-podcast-7831901/q1-company-news-roundup-with-wall-street-analyst-kyle-mikson.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}